|
1
|
Fan L, Strasser-Weippl K, Li JJ, St Louis
J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast
cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis CE, Ma J, Sauer Goding A, Newman
LA and Jemal A: Breast cancer statistics, 2017, racial disparity in
mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Slamon D, Clark G, Wong S, Levin W,
Ullrich A and McGuire W: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Press MF, Bernstein L, Thomas PA, Meisner
LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C and El-Naggar A:
HER-2/neu gene amplification characterized by fluorescence in situ
hybridization: poor prognosis in node-negative breast carcinomas. J
Clin Oncol. 15:2894–2904. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Olayioye MA, Neve RM, Lane HA and Hynes
NE: The ErbB signaling network: Receptor heterodimerization in
development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dawood S, Broglio K, Buzdar AU, Hortobagyi
GN and Giordano SH: Prognosis of women with metastatic breast
cancer by HER2 status and trastuzumab treatment: An
institutional-based review. J Clin Oncol. 28:92–98. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ross JS, Slodkowska EA, Symmans WF,
Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and
breast cancer: Ten years of targeted anti-HER-2 therapy and
personalized medicine. Oncologist. 14:320–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Akiyama T, Sudo C, Ogawara H, Toyoshima K
and Yamamoto T: The product of the human c-erbB-2 gene: A
185-kilodalton glycoprotein with tyrosine kinase activity. Science.
232:1644–1646. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Belengeanu A, Muresan A, Stoicanescu D and
Lazar E: Amplification of HER-2 gene in breast cancer:
Immunohistochemical and FISH assessment. Rom J Morphol Embryol.
51:321–326. 2010.PubMed/NCBI
|
|
10
|
Piccart-Gebhart MJ, Procter M,
Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga
J, Bell R, Jackisch C, et al: Trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer. N Engl J Med.
353:1659–1672. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Smith I, Procter M, Gelber RD, Guillaume
S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G,
Baselga J, et al: 2-year follow-up of trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer: A randomised
controlled trial. Lancet. 369:29–36. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rugo HS, Li H and Gui X: Strategies and
progress of endocrine therapy for patients with metastatic breast
cancer. Adv Exp Med Biol. 1026:403–418. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gianni L, Bisagni G, Colleoni M, Del
Mastro L, Zamagni C, Mansutti M, Zambetti M, Frassoldati A, De Fato
R, Valagussa P and Viale G: Neoadjuvant treatment with trastuzumab
and pertuzumab plus palbociclib and fulvestrant in HER2-positive,
ER-positive breast cancer (NA-PHER2): An exploratory, open-label,
phase 2 study. Lancet Oncol. 19:249–256. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brugmann A, Lelkaitis G, Nielsen S, Jensen
KG and Jensen V: Testing HER2 in breast cancer: A comparative study
on BRISH, FISH and IHC. Appl Immunohistochem Mol Morphol.
19:203–211. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De Mattos-Arruda L: Liquid biopsy for
HER2-positive breast cancer brain metastasis: The role of the
cerebrospinal fluid. ESMO Open. 2:e0002702017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Apostolaki S, Perraki M, Kallergi G,
Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N,
Kalmanti L, Kalbakis K, et al: Detection of occult HER2
mRNA-positive tumor cells in the peripheral blood of patients with
operable breast cancer: Evaluation of their prognostic relevance.
Breast Cancer Res Treat. 117:525–534. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Apostolaki S, Perraki M, Pallis A,
Bozionelou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E,
Kalbakis K, Kalykaki A, et al: Circulating HER2 mRNA-positive cells
in the peripheral blood of patients with stage I and II breast
cancer after the administration of adjuvant chemotherapy:
Evaluation of their clinical relevance. Ann Oncol. 18:851–858.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Savino M, Garrubba M, Parrella P, Baorda
F, Copetti M, Murgo R, Zelante L, Carella M, Valori VM and Santini
SA: Development of real-time quantitative reverse transcription-PCR
for Her2 detection in peripheral blood from patients with breast
cancer. Clin Chim Acta. 384:52–56. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Korantzis I, Kalogeras KT, Papaxoinis G,
Kotoula V, Koutras A, Soupos N, Papakostas P, Dionysopoulos D,
Samantas E, Christodoulou C, et al: Expression of angiogenic
markers in the peripheral blood of patients with advanced breast
cancer treated with weekly docetaxel. Anticancer Res. 32:4569–4580.
2012.PubMed/NCBI
|
|
21
|
Owrangi B, Habibagahi M, Hosseini A,
Haghighi NF, Mardani M, Talei A, Ghaderi A and Jaberipour M: MDM2,
E-cadherin, Survivin and Her2 mRNA status in peripheral blood of
patients with breast cancer. Mid East J Cancer. 4:2013.
|
|
22
|
Press MF, Sauter G, Buyse M, Fourmanoir H,
Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown
J, et al: HER2 gene amplification testing by fluorescent in situ
hybridization (FISH): Comparison of the ASCO-College of American
Pathologists Guidelines With fish scores used for enrollment in
breast cancer international research group clinical trials. J Clin
Oncol. 34:3518–3528. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Malzkorn B and Reifenberger G: Practical
implications of integrated glioma classification according to the
World Health Organization classification of tumors of the central
nervous system. Curr Opin Oncol. 28(494–501): 20162016.
|
|
24
|
Fleige S and Pfaffl MW: RNA integrity and
the effect on the real-time qRT-PCR performance. Mol Aspects Med.
27:126–139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
El Hadi H, Abdellaoui-Maane I, Kottwitz D,
El Amrani M, Bouchoutrouch N, Qmichou Z, Karkouri M, ElAttar H,
Errihani H, Fernandez PL, et al: Development and evaluation of a
novel RT-qPCR based test for the quantification of HER2 gene
expression in breast cancer. Gene. 605:114–122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leslie DS, Johnston WW, Daly L, Ring DB,
Shpall EJ, Peters WP and Bast RC Jr: Detection of breast carcinoma
cells in human bone marrow using fluorescence-activated cell
sorting and conventional cytology. Ame J Clin Pathol. 94:8–13.
1990. View Article : Google Scholar
|
|
28
|
Catenacci DV, Liao WL, Zhao L, Whitcomb E,
Henderson L, O'Day E, Xu P, Thyparambil S, Krizman D, Bengali K, et
al: Mass-spectrometry-based quantitation of Her2 in
gastroesophageal tumor tissue: Comparison to IHC and FISH. Gastric
Cancer. 19:1066–1079. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Check W: IHC, FISH still sharing HER2
spotlight. CAP Today. 19(1): 4042 passim. 2005.
|
|
30
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 world health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Caraguel CG, Stryhn H, Gagne N, Dohoo IR
and Hammell KL: Selection of a cutoff value for real-time
polymerase chain reaction results to fit a diagnostic purpose:
Analytical and epidemiologic approaches. J Vet Diagn Invest.
23:2–15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jensen LR, Huuse EM, Bathen TF, Goa PE,
Bofin AM, Pedersen TB, Lundgren S and Gribbestad IS: Assessment of
early docetaxel response in an experimental model of human breast
cancer using DCE-MRI, ex vivo HR MAS and in vivo 1H MRS. NMR
Biomed. 23:56–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao X, Rodland EA, Tibshirani R and
Plevritis S: Molecular subtyping for clinically defined breast
cancer subgroups. Breast Cancer Res. 17:292015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yan J, Liu XL, Han LZ, Xiao G, Li NL, Deng
YN, Yin LC, Ling LJ, Yu XY, Tan CL, et al: Relation between Ki-67,
ER, PR, Her2/neu, p21, EGFR and TOP II-α expression in invasive
ductal breast cancer patients and correlations with prognosis.
Asian Pac J Cancer Prev. 16:823–829. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tsuda H: HER-2 (c-erbB-2) test update:
Present status and problems. Breast Cancer. 13:236–248. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hall C, Valad L and Lucci A: Circulating
tumor cells in breast cancer patients. Crit Rev Oncog. 21:125–139.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang HY, Ahn S, Kim S, Park S, Jung D,
Park S, Han H, Sohn J, Kim S and Lee H: Detection of circulating
tumor cell-specific markers in breast cancer patients using the
quantitative RT-PCR assay. Int J Clin Oncol. 20:878–890. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Janjigian YY, Riches JC, Ku GY, Imatiaz T,
Capanu M and Chou JF: Loss of human epidermal growth factor
receptor 2 (HER2) expression in HER2-overexpressing esophagogastric
(EG) tumors treated with trastuzumab. Gastrointesti Cancers
Symposium. 2015.
|
|
39
|
Crowley E, Di Nicolantonio F, Loupakis F
and Bardelli A: Liquid biopsy: Monitoring cancer-genetics in the
blood. Nat Rev Clin Oncol. 10:472–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Raitoharju E, Seppala I, Oksala N,
Lyytikäinen LP, Raitakari O, Viikari J, Ala-Korpela M, Soininen P,
Kangas AJ, Waldenberger M, et al: Blood microRNA profile associates
with the levels of serum lipids and metabolites associated with
glucose metabolism and insulin resistance and pinpoints pathways
underlying metabolic syndrome: The cardiovascular risk in Young
Finns Study. Mol Cell Endocrinol. 391:41–49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Koumarianou A, Karayannopoulou G,
Gourgioti G, Batistatou A, Bobos M, Efstratiou I, Miliaras D,
Galani E, Pentheroudakis G, Pectasides D, et al: PAI-1 and HER2
interaction in advanced breast cancer disease: Evidence for added
benefit from trastuzumab in HER2-negative patients. Cancer
Chemother Pharmacol. 75:1289–1301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hudis CA: Biology before anatomy in early
breast cancer-precisely the point. N Engl J Med. 373:2079–2080.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Savino M, Parrella P, Copetti M, Barbano
R, Murgo R, Fazio VM, Valori VM, Carella M, Garrubba M and Santini
SA: Comparison between real-time quantitative PCR detection of HER2
mRNA copy number in peripheral blood and ELISA of serum HER2
protein for determining HER2 status in breast cancer patients. Cell
Oncol. 31:203–211. 2009.PubMed/NCBI
|
|
44
|
Al Diffalha S, Shaar M, Barkan GA, Wojcik
EM, Picken MM and Pambuccian SE: Immunohistochemistry in the workup
of prostate biopsies: Frequency, variation and appropriateness of
use among pathologists practicing at an academic center. Ann Diagn
Pathol. 27:34–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Allison KH: Molecular pathology of breast
cancer: What a pathologist needs to know. Am J Clin Pathol.
138:770–780. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xu Y, Yao L, Li H, Ouyang T, Li J, Wang T,
Fan Z, Lin B, Lu Y, Larsson O and Xie Y: Presence of erbB2 mRNA in
the plasma of breast cancer patients is associated with circulating
tumor cells and negative estrogen and progesterone receptor status.
Breast Cancer Res Treat. 97:49–55. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Oloomi M, Bouzari S, Mohagheghi MA and
Khodayaran-Tehrani H: Molecular markers in peripheral blood of
Iranian women with breast cancer. Cancer Microenviron. 6:109–116.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Moazzezy N, Ebrahimi F, Sisakht MM,
Yahyazadeh H, Bouzari S and Oloomi M: Relationship between erb-B2
mRNA expression in blood and tissue of invasive ductal carcinoma
breast cancer patients and clinicopathological characteristics of
the tumors. Asian Pac J Cancer Prev. 17:249–254. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tse C, Brault D, Gligorov J, Antoine M,
Neumann R, Lotz JP and Capeau J: Evaluation of the quantitative
analytical methods real-time PCR for HER-2 gene quantification and
ELISA of serum HER-2 protein and comparison with fluorescence in
situ hybridization and immunohistochemistry for determining HER-2
status in breast cancer patients. Clin Chem. 51:1093–1101. 2005.
View Article : Google Scholar : PubMed/NCBI
|
